Vaccines for low-income countries
- PMID: 23757292
- DOI: 10.1016/j.smim.2013.05.004
Vaccines for low-income countries
Abstract
Low-income countries typically lag behind industrialised nations, where the introduction of new vaccines is commonly tailored to the pressures of the commercial market. Happily in recent years this paradigm has started to change with the introduction of a univalent meningococcal A conjugate vaccine that is specifically targeted for the prevention of epidemic meningitis in Africa. The declaration of the 2010s as a New Decade of Vaccines, together with Millennium Development Goals 4 and 5, provide a strong mandate for a new approach to the development of vaccines for low-income countries, so that there has never been a more exciting time to work in this field. This review considers the opportunities and challenges of developing these new vaccines in the context of innovations in vaccinology, the need to induce protective immunity in the populations at risk and the requirement for strong partnership between the countries that will use these vaccines and different elements of the vaccine industry.
Keywords: Adjuvants; Conjugate vaccines; GMMA; Genomics; Global health; Immunisation; Low-income countries; Reverse vaccinology; Vaccines.
Copyright © 2013 The Author. Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa.Vaccine. 2009 Mar 23;27(14):2023-9. doi: 10.1016/j.vaccine.2008.11.092. Epub 2008 Dec 16. Vaccine. 2009. PMID: 19095025 Review.
-
The Meningitis Vaccine Project.Vaccine. 2007 Sep 3;25 Suppl 1:A97-100. doi: 10.1016/j.vaccine.2007.04.049. Epub 2007 May 7. Vaccine. 2007. PMID: 17521780
-
Can we defeat meningococcal disease in low and middle income countries?Vaccine. 2012 May 30;30 Suppl 2:B63-6. doi: 10.1016/j.vaccine.2011.12.063. Vaccine. 2012. PMID: 22607901 Review.
-
Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project.J Health Popul Nutr. 2004 Sep;22(3):275-85. J Health Popul Nutr. 2004. PMID: 15609780
-
Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.Vaccine. 2005 Aug 31;23(37):4610-8. doi: 10.1016/j.vaccine.2005.04.044. Vaccine. 2005. PMID: 15979769
Cited by
-
Vaccination willingness, vaccine hesitancy, and estimated coverage of SARS-CoV-2 vaccine among healthcare workers in Tanzania: A call for action.Immun Inflamm Dis. 2023 Dec;11(12):e1126. doi: 10.1002/iid3.1126. Immun Inflamm Dis. 2023. PMID: 38156379 Free PMC article.
-
Impact of the Host Microbiome on Vaccine Responsiveness: Lessons Learned and Future Perspective.Biochemistry. 2022 Dec 20;61(24):2849-2855. doi: 10.1021/acs.biochem.2c00309. Epub 2022 Aug 22. Biochemistry. 2022. PMID: 35993915 Free PMC article. Review.
-
Potential global impacts of alternative dosing regimen and rollout options for the ChAdOx1 nCoV-19 vaccine.Nat Commun. 2021 Nov 4;12(1):6370. doi: 10.1038/s41467-021-26449-8. Nat Commun. 2021. PMID: 34737262 Free PMC article.
-
Costs related to immunopreventable diseases: Brazil and its geographic areas (immunopreventable diseases' costs in Brazil).BMC Health Serv Res. 2021 Oct 27;21(1):1165. doi: 10.1186/s12913-021-07117-5. BMC Health Serv Res. 2021. PMID: 34706728 Free PMC article.
-
Long-Term Anti-Bacterial Immunity against Systemic Infection by Salmonella enterica Serovar Typhimurium Elicited by a GMMA-Based Vaccine.Vaccines (Basel). 2021 May 12;9(5):495. doi: 10.3390/vaccines9050495. Vaccines (Basel). 2021. PMID: 34065899 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
